8 reports

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Blood Disease
  • Immunotherapy
  • Ophthalmology
  • Protein Therapy

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Ophthalmology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

The drug candidate binds to and inhibits the mRNA of Orai ##, inhibiting the calcium transport.

  • Antifungal
  • Ophthalmic Solution
  • Ophthalmology
  • Protein Therapy
  • Therapy

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Infectious Disease
  • Ophthalmology
  • Protein Therapy
  • Therapy

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Gene Therapy
  • Ophthalmology
  • Protein Therapy
  • Therapy

Subjects orally took study drug once daily in the evening for one month.

  • Eye Disease
  • Ophthalmology
  • Protein Therapy
  • United States
  • Product Initiative

(allergy and autoimmune diagnostics) which was sold to Thermo Fisher Scientific (TMO) in September of 2011.

  • Gene Therapy
  • Ophthalmology
  • Pharmaceutical
  • Protein Therapy
  • Therapy

The drug candidate is a ##-imino-##, ##, ##-thiadiazole derivative.

  • Ophthalmology
  • Pharmaceutical
  • Protein Therapy
  • United States
  • Product Initiative